Liquidia Co. (NASDAQ:LQDA - Get Free Report) insider Rajeev Saggar sold 2,526 shares of the stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $11.19, for a total value of $28,265.94. Following the transaction, the insider now directly owns 204,857 shares in the company, valued at approximately $2,292,349.83. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Rajeev Saggar also recently made the following trade(s):
- On Monday, October 14th, Rajeev Saggar sold 2,260 shares of Liquidia stock. The stock was sold at an average price of $11.11, for a total transaction of $25,108.60.
Liquidia Trading Up 1.0 %
NASDAQ:LQDA traded up $0.11 during mid-day trading on Tuesday, hitting $11.20. The company's stock had a trading volume of 605,370 shares, compared to its average volume of 1,002,025. The company has a market capitalization of $855.84 million, a price-to-earnings ratio of -7.18 and a beta of 0.22. Liquidia Co. has a fifty-two week low of $6.04 and a fifty-two week high of $16.99. The stock has a fifty day moving average of $10.35 and a 200-day moving average of $11.83.
Liquidia (NASDAQ:LQDA - Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.02). The company had revenue of $3.66 million during the quarter, compared to analyst estimates of $7.92 million. Liquidia had a negative return on equity of 183.57% and a negative net margin of 755.46%. On average, equities analysts anticipate that Liquidia Co. will post -1.69 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Liquidia
Institutional investors and hedge funds have recently made changes to their positions in the company. Patient Square Capital LP bought a new position in Liquidia during the 1st quarter valued at about $105,942,000. Farallon Capital Management LLC bought a new position in shares of Liquidia in the first quarter valued at approximately $30,311,000. Sapient Capital LLC bought a new position in shares of Liquidia in the third quarter valued at approximately $1,336,000. BNP Paribas Financial Markets boosted its holdings in shares of Liquidia by 119.4% in the 1st quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company's stock worth $3,396,000 after acquiring an additional 125,315 shares in the last quarter. Finally, HighVista Strategies LLC bought a new stake in Liquidia during the 2nd quarter worth approximately $1,461,000. Institutional investors and hedge funds own 64.54% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on LQDA shares. Needham & Company LLC reissued a "buy" rating and set a $25.00 price objective on shares of Liquidia in a research report on Monday, August 19th. BTIG Research reduced their price objective on Liquidia from $29.00 to $25.00 and set a "buy" rating for the company in a research report on Monday, August 19th. Raymond James raised shares of Liquidia from an "outperform" rating to a "strong-buy" rating in a research report on Monday, August 19th. Bank of America reduced their price target on shares of Liquidia from $24.00 to $23.00 and set a "buy" rating for the company in a report on Tuesday, August 20th. Finally, Scotiabank began coverage on shares of Liquidia in a research report on Wednesday, October 16th. They issued a "sector outperform" rating and a $30.00 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $24.67.
Read Our Latest Report on Liquidia
About Liquidia
(
Get Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Further Reading
Before you consider Liquidia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liquidia wasn't on the list.
While Liquidia currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
